All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study

Conclusion The combination of LC is active and well-tolerated treatment in patients with HER2+ve BCBM.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research